Size-Controlled Preparation of Docetaxel- and Curcumin-Loaded Nanoemulsions for Potential Pulmonary Delivery DOI Creative Commons
Azren Aida Asmawi, Norazlinaliza Salim, Emilia Abdulmalek

et al.

Pharmaceutics, Journal Year: 2023, Volume and Issue: 15(2), P. 652 - 652

Published: Feb. 15, 2023

Lung cancer is one of the deadliest pulmonary diseases in world. Although docetaxel (DTX) has exhibited superior efficacy lung treatment, it demonstrated numerous adverse effects and poor bioavailability. The natural product extract, curcumin (CCM), reportedly reduced toxicity synergistically improved DTX Nonetheless, hydrophobic nature CCM limits their clinical use. Nanoemulsion delivery potential as a drug carrier to alleviate these drawbacks. controlled preparation inhalable DTX- CCM-loaded nanoemulsions within 100 200 nm range was explored this study. A response surface methodology (RSM) based on central composite design (CCD) utilized fabricate desired size nanoemulsion under optimized conditions. Different process parameters were employed control procured through high-energy emulsification technique. resultant decreased with increasing energy input. actual according targeted sizes for models excellent agreement predicted value at below 5% residual standard error particle better membrane permeability than larger counterparts. Moreover, formulations documented favorable physicochemical aerodynamic properties human fibroblast (MRC-5) cells. Hence, tunable could be suitable alternative increased local concentration.

Language: Английский

Fatal COVID-19 pulmonary disease involves ferroptosis DOI Creative Commons
Baiyu Qiu, Fereshteh Zandkarimi, Anjali Saqi

et al.

Nature Communications, Journal Year: 2024, Volume and Issue: 15(1)

Published: May 20, 2024

Abstract SARS-CoV-2 infection causes severe pulmonary manifestations, with poorly understood mechanisms and limited treatment options. Hyperferritinemia disrupted lung iron homeostasis in COVID-19 patients imply that ferroptosis, an iron-dependent cell death, may occur. Immunostaining lipidomic analysis autopsies reveal increases ferroptosis markers, including transferrin receptor 1 malondialdehyde accumulation fatal cases. lungs display dysregulation of lipids involved metabolism ferroptosis. We find increased ferritin light chain associated pathology. Iron overload promotes both primary cells cancerous epithelial cells. In addition, markers strongly correlate injury severity a disease model using male Syrian hamsters. These results role for disease; pharmacological inhibition serve as adjuvant therapy to prevent damage during infection.

Language: Английский

Citations

20

Advances and future perspectives of intranasal drug delivery: A scientometric review DOI
Dong Xu, Xujiao Song,

Xue Chen

et al.

Journal of Controlled Release, Journal Year: 2024, Volume and Issue: 367, P. 366 - 384

Published: Feb. 1, 2024

Language: Английский

Citations

19

Targeted delivery of TGF-β mRNA to murine lung parenchyma using one-component ionizable amphiphilic Janus Dendrimers DOI Creative Commons
J. Meshanni, Emily Stevenson, Dapeng Zhang

et al.

Nature Communications, Journal Year: 2025, Volume and Issue: 16(1)

Published: Feb. 21, 2025

Language: Английский

Citations

4

Bacterial outer membrane vesicles-based therapeutic platform eradicates triple-negative breast tumor by combinational photodynamic/chemo-/immunotherapy DOI Creative Commons
Yongjiang Li, Junyong Wu,

Xiaohan Qiu

et al.

Bioactive Materials, Journal Year: 2022, Volume and Issue: 20, P. 548 - 560

Published: June 29, 2022

Bacterial outer membrane vesicles (OMVs) are potent immuno-stimulating agents and have the potentials to be bioengineered as platforms for antitumor nanomedicine. In this study, OMVs demonstrated promising therapeutics. can lead beneficial M2-to-M1 polarization of macrophages induce pyroptosis enhance immunity, but therapeutic window is narrow its toxicity. We propose a bioengineering strategy tumor-targeting ability by macrophage-mediated delivery improve efficacy co-loading photosensitizer chlorin e6 (Ce6) chemotherapeutic drug doxorubicin (DOX) into platform. demonstrate that systemic injection DOX/Ce6-OMVs@M platform, providing combinational photodynamic/chemo-/immunotherapy, eradicates triple-negative breast tumors in mice without side effects. Importantly, also effectively prevents tumor metastasis lung. This OMVs-based with may serve powerful platform synergic therapy.

Language: Английский

Citations

66

mRNA nanodelivery systems: targeting strategies and administration routes DOI Creative Commons
Mujie Yuan, Zeyu Han, Yan Liang

et al.

Biomaterials Research, Journal Year: 2023, Volume and Issue: 27(1)

Published: Feb. 9, 2023

With the great success of coronavirus disease (COVID-19) messenger ribonucleic acid (mRNA) vaccines, mRNA therapeutics have gained significant momentum for prevention and treatment various refractory diseases. To function efficiently in vivo overcome clinical limitations, demands safe stable vectors a reasonable administration route, bypassing multiple biological barriers achieving organ-specific targeted delivery mRNA. Nanoparticle (NP)-based systems representing leading vector approaches ensure successful intracellular to target organ. In this review, chemical modifications types advanced NPs, including lipid NPs polymers are summarized. The importance passive targeting, especially endogenous active targeting nano-delivery is emphasized, different cellular endocytic mechanisms discussed. Most importantly, based on above content physiological structure characteristics organs vivo, design strategies cells classified Furthermore, influence routes highlighted. Finally, an outlook remaining challenges future development toward therapies precision medicine provided.

Language: Английский

Citations

35

Dry Powder Inhaler with the technical and practical obstacles, and forthcoming platform strategies DOI
Sachin S. Gaikwad,

Snehal R. Pathare,

Mayur A. More

et al.

Journal of Controlled Release, Journal Year: 2023, Volume and Issue: 355, P. 292 - 311

Published: Feb. 9, 2023

Language: Английский

Citations

32

Nanocarriers in Tuberculosis Treatment: Challenges and Delivery Strategies DOI Creative Commons

Mahesh Kumar,

Tarun Virmani, Girish Kumar

et al.

Pharmaceuticals, Journal Year: 2023, Volume and Issue: 16(10), P. 1360 - 1360

Published: Sept. 26, 2023

The World Health Organization identifies tuberculosis (TB), caused by Mycobacterium tuberculosis, as a leading infectious killer. Although conventional treatments for TB exist, they come with challenges such heavy pill regimen, prolonged treatment duration, and strict schedule, to multidrug-resistant (MDR) extensively drug-resistant (XDR) strains. rise of MDR strains endangers future control. Despite these concerns, the hunt an efficient continues. One breakthrough has been use nanotechnology in medicines, presenting novel approach treatment. Nanocarriers, lipid nanoparticles, nanosuspensions, liposomes, polymeric micelles, facilitate targeted delivery anti-TB drugs. benefits nanocarriers include reduced drug doses, fewer side effects, improved solubility, better bioavailability, patient compliance, speeding up recovery. Additionally, can be made even more linking them ligands mannose or hyaluronic acid. This review explores innovative treatments, including studies on containing drugs related patents.

Language: Английский

Citations

28

A multiplex inhalation platform to model in situ like aerosol delivery in a breathing lung-on-chip DOI Creative Commons
Arunima Sengupta,

Aurélien Dorn,

Mohammad Jamshidi

et al.

Frontiers in Pharmacology, Journal Year: 2023, Volume and Issue: 14

Published: March 6, 2023

Prolonged exposure to environmental respirable toxicants can lead the development and worsening of severe respiratory diseases such as asthma, chronic obstructive pulmonary disease (COPD) fibrosis. The limited number FDA-approved inhaled drugs for these serious lung conditions has led a shift from in vivo towards use alternative vitro human-relevant models better predict toxicity particles preclinical research. While there are several inhalation upper airways, fragile dynamic nature alveolar microenvironment reproducible distal lung. Here, we present mechanistic approach using new generation systems, Cloud α AX12. This novel tool consists cloud-based chamber (VITROCELL) that integrates breathing AX Lung-on-chip system (AlveoliX). ultrathin porous membrane AX12 plate was used create complex multicellular model enables key physiological culture conditions: air-liquid interface (ALI) three-dimensional cyclic stretch (CS). Human-relevant cellular were established a) alveolar-capillary primary cell-derived immortalized epithelial cells ( iAECs), macrophages (THP-1) endothelial (HLMVEC) cells, b) upper-airways Calu3 cells. Primary human hAEpCs) validate results obtained cell lines. To mimic relevant aerosol exposures with AX12, three different using: titanium dioxide (TiO2) zinc oxide nanoparticles polyhexamethylene guanidine toxic chemical c) an anti-inflammatory corticosteroid, fluticasone propionate (FL). Our suggest important synergistic effect on air-blood barrier sensitivity, cytotoxicity inflammation, when combined. best our knowledge, this is first time been described lung-on-chip technology. thus represents state-of-the-art pre-clinical study risks, drug safety efficacy.

Language: Английский

Citations

25

Advancements in Chitosan-Based Nanoparticles for Pulmonary Drug Delivery DOI Open Access
Thiago Medeiros Zacaron, Mariana Leite Simões e Silva, Mirsiane Pascoal Costa

et al.

Polymers, Journal Year: 2023, Volume and Issue: 15(18), P. 3849 - 3849

Published: Sept. 21, 2023

The evolution of respiratory diseases represents a considerable public health challenge, as they are among the leading causes death worldwide. In this sense, in addition to high prevalence such asthma, chronic obstructive pulmonary disease, pneumonia, cystic fibrosis, and lung cancer, emerging diseases, particularly those caused by members coronavirus family, have contributed significant number deaths on global scale over last two decades. Therefore, several studies been conducted optimize efficacy treatments against these focusing drug delivery using nanomedicine. Thus, development nanocarriers has emerged promising alternative overcome limitations conventional therapy, increasing bioavailability at target site reducing unwanted side effects. context, nanoparticles composed chitosan (CS) show advantages other because possesses intrinsic biological properties, anti-inflammatory, antimicrobial, mucoadhesive capacity. Moreover, CS potential enhance stability, prolong duration action, improve targeting, control release, dissolution poorly soluble drugs, increase cell membrane permeability hydrophobic drugs. These properties could performance after its administration. review aims discuss for delivery, highlighting how their can treatment including synergistic action with encapsulated drug.

Language: Английский

Citations

24

Cell-mediated nanoparticle delivery systems: towards precision nanomedicine DOI Creative Commons
Ruoyu Cheng, Shiqi Wang

Drug Delivery and Translational Research, Journal Year: 2024, Volume and Issue: 14(11), P. 3032 - 3054

Published: April 13, 2024

Cell-mediated nanoparticle delivery systems (CMNDDs) utilize cells as carriers to deliver the drug-loaded nanoparticles. Unlike traditional drug approaches, CMNDDs take advantages of cell characteristics, such homing capabilities stem cells, inflammatory chemotaxis neutrophils, prolonged blood circulation red and internalization macrophages. Subsequently, can easily prolong circulation, cross biological barriers, blood-brain barrier bone marrow-blood barrier, rapidly arrive at diseased areas. Such advantageous properties make promising candidates for precision targeting. In this review, we summarize recent advances in fabrication biomedical applications. Specifically, ligand-receptor interactions, non-covalent covalent are commonly applied constructing vitro. By hitchhiking macrophages, monocytes, platelets, nanoparticles be internalized or attached construct vivo. Then highlight application treating different diseases, cancer, central nervous system disorders, lung cardiovascular with a brief discussion about challenges future perspectives end.

Language: Английский

Citations

14